NCRM-5, NL-5
CRMi001-A
General
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | fetal |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes |
|
External Databases (Donor) |
|
| BioSamples | SAMEA7774918 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Please provide contact information of the holder of the original Donor Information Sheet. | |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please provide the contact information | |
| Alternatives to consent | |
| Alternative consent approval number | |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Please describe how access is provided: | |
| Contact data, institution, or website: | |
| Name of accrediting authority involved? | Redacted form available from distributor |
| Approval number | |
| Name of accrediting authority involved? | Redacted form available from distributor |
| Approval number | |
| Please describe: | |
| Further constraints on use | |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Constraints for use or distribution | |
hIPSC Derivation
General |
|
| Source cell origin |
Blood that remains in the placenta and in the attached umbilical cord after childbirth[WP].; Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders.[WP]
Synonyms
|
| Source cell type (free text) | Cord Blood CD34+ cells |
| Age of donor (at collection) | fetal |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | Colony morphology and alkaline phosphatase expression |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Dispase
|
| O2 Concentration | 4 % |
| CO2 Concentration | 5 % |
| Medium | mTeSR™ 1 |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
12
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.